The Food and Drug Administration has received a new application from Sprout Pharmaceutical for approval of Flibanserin as a libido booster for women. The FDA has twice refused approval of Flibanserin because of side effects, which included fatigue, dizziness and nausea, and also because of lackluster effectiveness. Sprout re-filed its application and included new information that the FDA had requested from them about how Flibanserin affects the ability of women to drive.
By using an engineered strain of lactobacillus (human probiotics common in the gut of the body) that would secrete a Glucagen-like peptide (GPL-1), researchers saw that the engineered probiotic created up to a 30 percent lower high blood glucose in rats with diabetes. The team orally administered the engineered probiotics for 90 days to the rats.
Older diabetics striving for a higher A1C? Older patients with multiple medical conditions might see their blood sugar levels drop to a dangerously low point when taking different medications for different health problems, so the usual aggressive control of those low A1c numbers might do more harm than good by causing hypoglycemia (low blood sugar levels), which can lead to confusion, coma, and even death.
Results of a study conducted by Mailman School of Public Health at Columbia University and Harvard School of Public Health show that women who are suffering from post-traumatic stress disorder are nearly twice as likely to develop type 2 diabetes when compared with women who don’t have PTSD.
A proof-of-concept study, scheduled to be published in the American Chemical Society’s journal Analytical Chemistry in the near future and submitted by Joseph Wang and colleagues at the University of California San Diego, indicates that a rub-on, tattoo-like sensor that sticks to the skin that they have developed can detect glucose levels.